PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media31314610.18565/pharmateca.2021.5.76-80ArticlesСтатьиResearch ArticlePatients with bronchial asthma who have undergone COVID-19Больные бронхиальной астмой, перенесшие COVID-19TrushinaElena Yu.ТрушинаЕ. Ю

Cand. Sci. (Med.), Teaching Assistant at the Department of Pulmonology and Phthisiology

к.м.н., ассистент кафедры пульмонологии и фтизиатрии

trushina.lena@mail.ruKostinaE. MКостинаЕ. МOrlovaE. AОрловаЕ. АPenza Institute for Advanced Medical Education - Branch Campus of the Russian Medical Academy of Continuous Professional EducationПензенский институт усовершенствования врачей - филиал ФГБОУ ДПО РМАНПО Минздрава РФ15052021285VOL 28, NO5 (2021)ТОМ 28, №5 (2021)768003032023Copyright ©; 2021, Bionika MediaCopyright ©; 2021, ООО «Бионика Медиа»2021Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/313146

Background. Coronavirus infection 2019 (COVID-19) is common worldwide. The significance of bronchial asthma (BA) for the course of COVID-19 is ambiguous. Objective. Retrospectively analysis of the course of COVID-19 infection in BA patients. Methods. The case histories of 1167 patients diagnosed with COVID-19, among them 82 (7.02%) patients suffered from BA, were analyzed. Results. Among BA patients who underwent COVID-19 infection, there were 11 (13.4%) men and 71 (86.6%) women. Among BA patients, diabetes mellitus was found in 5 (6.09%), arterial hypertension - in 70 (85.4%), coronary artery disease - in 8 (9.75%) patients. 5 BA patients died. There were 7 smoking BA patients. Conclusion. The analysis showed that the prevalence of BA was 7.02% of the total number of COVID-19 infections. Low mortality was revealed in BA patients infected with COVID-19.

Обоснование. Коронавирусная инфекция 2019 г. (COVID-19) распространена во всем мире. Значение бронхиальной астмы (БА) на течение COVID-19 неоднозначно. Цель исследования: ретроспективно проанализировать течение инфекции COVID-19 у больных БА. Методы. Проведен анализ документации 1167 пациентов с диагнозом COVID-19, среди них 82 (7,02%) пациента страдали БА. Результаты. Среди больных БА, перенесших инфекцию COVID-19, мужчин было 11 (13,4%) , женщин - 71 (86,6%). Среди больных БА сахарный диабет встречался у 5 (6,09%) человек, артериальная гипертензия у 70 (85,4%), ишемическая болезнь сердца у 8 (9,75%). Среди больных БА умерли 5 человек. Курящие больные БА составили 7 человек. Заключение. Проведенный анализ показал, что распространенность БА составляла 7,02% от общего числа инфекций COVID-19. Выявлена низкая смертность среди больных БА, инфицированных COVID-19.

COVID-19COVID-19bronchial asthmacomorbid diseasesбронхиальная астмакоморбидные заболеванияvan Doremalen N., Bushmaker T., Morris D.H., et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med. 2020;382(16):1564-67. Doi: 10.1056/ NEJMc2004973.Richardson S., Hirsch J.S., Narasimhan M., et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323(20):2052-59. Doi: 10.1001/ jama.2020.6775.Arentz M., Yim E., Klaff L., et al. Characteristics and Outcomes of 21Critically Ill Patients With COVID-19 in Washington State. JAMA. 2020;323(16):1612-14.Chhiba K.D., Patel G.B., Vu T.H., et al. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. J Allergy Clin Immunol. 2020;146(2):307-14. Doi: 10.1016/j.jaci.2020.06.010.Li X., Xu S., Yu M., et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110-18. Doi: 10.1016/j.jaci.2020.04.006.Johnston S.L. Asthma and COVID-19: Is asthma a risk factor for severe outcomes? Allergy. 2020;75(7):1543-45. doi: 10.1111/all.14348.Guia para el manejo del asma GEMA5.0. Available at: http://www.gemasma.com. Access date: 22.03.2021.Bhatraju P.K., Ghassemieh B.J., Nichols M., Kim R., et al. COVID-19 in Critically Ill Patients in the Seattle Region - Case Series. N Engl J Med. 2020:382(21):2012-22. Doi: 10.1056/ NEJMoa2004500.Garg S., et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020. MMWR. Morb Mortal Wkly Rep. 2020;69(15):458-64. Doi: 10.15585/mmwr. mm6915e3.Myers L.C., Parodi S.M., Escobar G.J., Liu V.X. Characteristics of Hospitalized Adults With COVID-19 in an Integrated Health Care System in California. JAMA. 2020;323(21):2195-98. Doi: 10.1001/jama.2020.7202.The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team (2020) The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) -China, 2020. China CDC weekly. February 17 2020.Grasselli C., Zangrillo A., Zanella A., et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574-81. Doi: 10.1001/ jama.2020.5394.Guan W.J., Liang W.H., Zhao Y., et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547. Doi: 10.1183/13993003.00547-2020.Zhang J.J., Dong X., Cao Y.Y., et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75(7):1730-41. doi.org/10.1111/ all.14238Dembic Z. Chapter 6 - cytokines of the immune system: interleukins. In: Dembic Z. (ed). The cytokines of the immunesystem. Amsterdam, Academic Press, 2015. Р 143-239. Doi: 10.1016/B978-0-12-419998-9.00006-7.de Velde A.A., Huijbens R.J., Heije K., et al. Interleukin-4 (IL-4) inhibits secretion of IL-1 beta, tumor necrosisfactor alpha, and IL-6 by human monocytes. Blood. 1990;76(7): 1392-97.Levings M.K., Schrader J.W. IL-4 inhibits the production of TNF-alpha and IL-12 by STAT6-dependent and - independent mechanisms. J Immunol. 1999;162(9):5224-29.de Vries J.E. The role of IL-13 and its receptor in allergy andinflammatory responses. J Allergy Clin Immunol. 1998;102(2):165-69. Doi: 10.1016/ s0091-6749(98)70080-6.Pilette C., Ouadrhiri Y, Van Snick J., et al. IL-9 inhibits oxidative burst and TNF-alpha release in lipopolysaccharide-stimulated human monocytesthrough TGF-beta. J Immunol. 2002;168(8):4103-1 1. Doi: 10.4049/ jimmunol.168.8.4103.Временные методические рекомендации по профилактике,диагностике и лечению новой коронавирусной инфекции (COVID-19). Версия 9 (26.10.2020). (Электронный ресурс).Jackson D.J., Busse W.W., Bacharier L.B., et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. J Allergy Clin Immunol. 2020;146(1):203-6. Doi: 10.1016/j.jaci.2020.04.009.Halpin D.M., Singh D., Hadfield R.M. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. Eur Respir J. 2020;55(5):2001009. Doi: 10.1183/13993003.01009-2020.Dong X., Cao Y.Y., Lu X.X., et al. Eleven faces of coronavirus disease 2019. Allergy. 2020;75(7): 1699-709. Doi: 10.1111/ all.14289.Arden K.E., Chang A.B., Lambert S.B., et al. Newly identified respiratory viruses in children with asthma exacerbation not requiring admission to hospital. J Med Virol. 2010;82:1458-61. Doi: 10.1002/jmv.21819.Johnston S.L., Pattemore P.K., Sanderson G., et al. The relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysis. Am J Respir Crit Care Med. 1996;154:654-60. Doi: 10.1164/ ajrccm.154.3.8810601.Khetsuriani N., Kazerouni N.N., Erdman D.D., et al. Prevalence of viral respiratory tract infections in children with asthma. J Allergy Clin Immunol. 2007;119:314-21. Doi: 10.1016/j. jaci.2006.08.041.Rosenberg H.F., Dyer K.D., Domachowske J.B. Respiratory viruses and eosinophils: exploring the connections. Antivir Res. 2009;83(1):1-9. Doi: 10.1016/j.antiviral.2009.04.005.Rosenberg H.F., Dyer K.D., Domachowske J.B. Eosinophil sand their interactions with respiratory virus pathogens. Immunol Res. 2009;43(1-3):128-37. Doi: 10.1007/s12026-008-8058-5.Du Y., Tu L., Zhu P., et al. Clinical features of 85 fatal casesof COVID-19 from Wuhan: a retrospective observational study. Am J Respir Crit Care Med. 2020;201:1372-9. Doi: 10.1164/ rccm.202003-0543OC.Hassani M., Leijte G., Bruse N., et al. Differentiation and activation of eosinophils in the human bone marrow during experimental human endotoxemia. J Leukoc Biol. 2020;108(5):1665-Doi: 10.1002/JLB.1AB1219-493R.Butterfield J.H. Treatment of hypereosinophilic syndromes with prednisone, hydroxyurea, and interferon. Immunol Allergy Clin North Am. 2007;27:493-518. Doi: 10.1016/j. iac.2007.06.003